Olymvax Bio Receives NMPA Approval for Clinical Study of Trivalent Influenza Vaccine
Olymvax Biopharmaceuticals Inc. (SHA: 688319), a leading vaccine specialist headquartered in Chengdu, has announced that...
SHA: 688319
Olymvax Bio Receives Ethical Approval for Oral Helicobacter pylori Vaccine Trial in Australia
Olymvax Biopharmaceuticals Inc. (SHA: 688319), a leading vaccine specialist headquartered in Chengdu, China, has announced...